

5 September 2006

Stem Cell Sciences plc

Notice of Interim Results

Stem Cell Sciences plc, the global stem cell company focused on the application of stem cell technologies to cell culture media, cell based drug screens and novel cell therapies, will be announcing interim results for the six months ended 30 June 2006 on Friday 15 September 2006.

- Ends-

Enquiries

Weber Shandwick Square Mile
James White

020 7067 0700

Notes to Editors:

Stem cells are undifferentiated (unspecialised) cells that can divide to make copies of themselves or differentiate (change) to become specialised cells of a specific tissue such as neural cells or blood cells.

Stem Cell Sciences plc (SCS, AIM: STEM) is a global biotechnology company focused on the development and application of stem cell technologies in biopharmaceutical research and cell-based therapies. The Company has established a leading intellectual property (IP) and technology portfolio that enables the commercial application of stem cells in pharmaceutical/ biotechnology drug discovery and development, providing the Company with an early-stage revenue stream. In the longer term, the Company is developing regenerative, cell-based therapies.

SCS operates as a group of independent operations with laboratories in Scotland, Japan and Australia, each of which is affiliated with an academic centre of excellence. These include the Institute of Stem Cell Research, Edinburgh, UK; RIKEN Centre for Development Biology, Kobe, Japan and the Australian Stem Cell Centre, Melbourne, Australia.

Stem Cell Sciences listed on the London AIM exchange on 18 July 2005 (AIM: STEM).